Skip to content

Cinnamon cuts blood glucose levels in diabetes patients

Lyra Nara Blog

Consumption of cinnamon is associated with favorable reductions in plasma glucose and lipid levels, according to research published in the September/October issue of the Annals of Family Medicine.

Robert W. Allen, Pharm.D., of the Western University of Health Sciences in Pomona, Calif., and colleagues used data from 10 randomized, controlled trials involving 543 patients with type 2 diabetes to conduct an update of a previous systematic review and meta-analysis examining the effect of cinnamon consumption on glucose and lipid levels.

The researchers found that cinnamon, in daily doses of 120 mg/d to 6 g/d for four to 18 weeks, was associated with a significant reduction in levels of fasting plasma glucose (?24.59 mg/dL), but no significant effect on glycosylated hemoglobin. Cinnamon intake also was linked to significant changes in lipid levels, including decreases in levels of total cholesterol (?15.60 mg/dL), low-density lipoprotein cholesterol (LDL-C) (?9.42 mg/dL), and triglycerides…

View original post 89 more words

Advertisements

LEUCODERMA CASE ; PROGRESSING FOR CURE ; सफेद दाग , लियूकोडर्मा का एक केस जिसे ई०टी०जी० आयुर्वेदास्कैन तकनीक आधारित आयुर्वेदिक इलाज से फायदा

PANOBINOSTAT

New Drug Approvals

Panobinostat

HDAC inhibitors, orphan drug

cas 404950-80-7 

2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide

N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide (alternatively, N-hydroxy-3-(4-{[2-(2-methyl-1H-indol-3-yl)-ethylamino]-methyl}-phenyl)-acrylamide)

Molecular Formula: C21H23N3O2   Molecular Weight: 349.42622

  • Faridak
  • LBH 589
  • LBH589
  • Panobinostat
  • UNII-9647FM7Y3Z

A hydroxamic acid analog histone deacetylase inhibitor from Novartis.

NOVARTIS, innovator

Histone deacetylase inhibitors

Is currently being examined in cutaneous T-cell lymphoma, CML and breast cancer.

clinical trials click here  phase 3

DRUG SUBSTANCE–LACTATE AS IN  http://www.google.com/patents/US7989639  SEE EG 31

Panobinostat (LBH-589) is an experimental drug developed by Novartis for the treatment of various cancers. It is a hydroxamic acid[1] and acts as a non-selective histone deacetylase inhibitor (HDAC inhibitor).[2]

panobinostat

Panobinostat is a cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the…

View original post 5,150 more words

Orphan Drugs: Global Regulatory Events

Merck Announces FDA Acceptance of New Drug Application for Investigational Fertility Treatment

New Drug Approvals

 

corifollitropin alfa

WHITEHOUSE STATION, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the New Drug Application (NDA) for its investigational fertility treatment, corifollitropin alfa, has been accepted for standard review by the U.S. Food and Drug Administration (FDA). Merck is seeking FDA approval of corifollitropin alfa for Controlled Ovarian Stimulation (COS) in women participating in assisted reproductive technology.

If approved, corifollitropin alfa would be the first sustained follicular stimulant for use in a fertility treatment regimen.

read all at

http://www.pharmalive.com/fda-accepts-mercks-fertility-treatment-nda

 

Corifollitropin alfa

Merck received approval on February 15, 2010 from the European Commission for ELONVA (corifollitropin alfa) a long lasting single injection fusion protein lacking LH activity. Only one injection is required for the first seven days, replacing the first seven daily injections of conventional FSH. Initial results demonstrates similar pregnancy rates as daily recombinant FSH injections.[7][8]

  1. ref 7…

View original post 331 more words

Pfizer’s Xalkori Granted Regular FDA Approval

New Drug Approvals

Pfizer’s XALKORI® Granted Regular FDA Approval
Standard of Care for Patients With Metastatic ALK-Positive Non-Small Cell Lung Cancer

NEW YORK, November 21, 2013–(BUSINESS WIRE)–Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Pfizer’s XALKORI® (crizotinib) regular approval for the treatment of patients with metastatic ALK-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. XALKORI was previously granted accelerated approval in August 2011 due to the critical need for new agents for people living with ALK-positive NSCLC

read all at

http://www.pharmalive.com/pfizer%E2%80%99s-xalkori-granted-regular-fda-approval

http://newdrugapprovals.wordpress.com/2013/03/01/pfizer-gains-china-approval-of-kinase-specific-lung-cancer-drug-xalkori-crizotinib/

View original post

Europace Publishes Data Supporting Use Of BRINAVESS™ (Vernakalant) As A First Line Agent For Pharmacological Cardioversion Of Atrial Fibrillation

New Drug Approvals

Vernakalant, MK-6621, RSD 1235

(3R)-1-{(1R,2R)-2-[2-(3,4-dimethoxyphenyl)
ethoxy]cyclohexyl}pyrrolidin-3-ol

C20H31NO4 ,  349.47, Brinavess , Kynapid

cas no 794466-70-9 
748810-28-8 (HCl)

EMA:Link  click here

PATENT   WO 2004099137

VANCOUVER, Nov. 21, 2013 /PRNewswire/ – Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that a publication titled, Pharmacological Cardioversion of Atrial Fibrillation with Vernakalant: Evidence in Support of the ESC Guidelines, was published in Europace, the official Journal of the European Heart Rhythm Association, and was made available in the advanced online article access section. The authors conclude that BRINAVESS is an efficacious and rapid acting pharmacological cardioversion agent, for recent-onset atrial fibrillation (AF,) that can be used first line in patients with little or no underlying cardiovascular disease and in patients with moderate disease, such as stable coronary and hypertensive heart disease.

http://www.prnewswire.com/news-releases/europace-publishes-data-supporting-use-of-brinavess-vernakalant-as-a-first-line-agent-for-pharmacological-cardioversion-of-atrial-fibrillation-232816731.html

Vernakalant (INN; codenamed RSD1235, proposed tradenames Kynapid and 

View original post 1,849 more words

Green Chemistry @ MUN

Less solvent, Less waste, Less energy

Lyra Nara Blog

modern holistic medicine, bioenergy devices, create your healthy journey

Developing the Process

Selected papers for the Process Development Chemist

Anthony Crasto's Transverse Mylitis Blog

Medicinal chemistry clips for you

Inspiring Science

Casting light on great ideas

pharmupdates.wordpress.com/

News and articles on the Pharmaceutical Industry

Colorblind Chemistry

Organometallic Chemistry with a Vengeance.

Metta Wellness

Where Massage and Wellness come together to create Balance of Mind, Body, Spirit , http://www.mettaspa.net

breastfedblog

A great WordPress.com site

Syntheticnature

Total Synthesis and general organic chemistry

Your mom is like science?

Practical scientific analogy education and outreach

NaturAsia

in English

RecallsDirect™ by Living Safely™

Official Site - An initiative of LivingSafely.org™, we report on food, product and vehicle recalls from various agencies in US, Canada, Europe and other jurisdictions.

TGI: Thrive Health

Share Knowledge & Save a Life

DRUG REGULATORY AFFAIRS INTERNATIONAL

Drug Regulatory affairs by DR ANTHONY MELVIN CRASTO, Worlddrugtracker

Seven Spheres

Aqua Terra Ignis et Aer

GreenChemBlog

Green Chemistry Awesomeness.

%d bloggers like this: